Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | CHOSA ONCOLOGY AB: CHOSA announces positive results from a clinical study in collaboration with ETOP/EORTC on platinum predictor in lung cancer | 2 | Cision News | ||
08.08. | CHOSA ONCOLOGY AB: CHOSA's presents data on the carboplatin response predictor in breast cancer patients on the annual ESMO conference | 2 | Cision News | ||
01.08. | Spotlight Stock Market: Market Notice 145/25 - Information regarding CHOSA Oncology AB's subscription option | 2 | Cision News | ||
01.08. | CHOSA ONCOLOGY AB: Chosa Oncology's warrants of series TO 2 to be admitted to trading | 1 | Cision News | ||
01.08. | Spotlight Stock Market: Market Notice 144/25 - Last day of trading in CHOSA Oncology AB's BTU | 2 | Cision News | ||
CHOSA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
31.07. | CHOSA ONCOLOGY AB: Chosa Oncology announces the last day of trading in BTU | 1 | Cision News | ||
31.07. | Spotlight Stock Market: Market Notice 143/25 - Trading halt in CHOSA Oncology AB's BTU | 1 | Cision News | ||
01.07. | CHOSA ONCOLOGY AB: CHOSA extends the timeline for biopsy collection prior to publication from the SPLENDOUR study | 1 | Cision News | ||
27.06. | CHOSA ONCOLOGY AB: Chosa Oncology announces outcome in rights issue | 2 | Cision News | ||
25.06. | CHOSA ONCOLOGY AB: Last subscription day in Chosa's subscription period | 2 | Cision News | ||
25.06. | CHOSA ONCOLOGY AB: CHOSA files new patent application to predict which patients may benefit from platinum chemotherapy and immunotherapy | 5 | Cision News | ||
13.06. | Bulletin from the annual general meeting on 13 June 2025 in Chosa Oncology AB | 1 | Cision News | ||
12.06. | The subscription period in Chosa Oncology AB's rights issue begins today - the company invites to a webcast presentation | 2 | Cision News | ||
10.06. | Chosa Oncology AB publishes information document in connection with rights issue of units | 2 | Cision News | ||
09.06. | CHOSA ONCOLOGY AB: CHOSA Oncology invites investors to two upcoming presentations | 1 | Cision News | ||
06.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.06.2025 | 346 | Xetra Newsboard | Das Instrument 37P FR0010341032 FONCIERE INEA SA EO 14,39 EQUITY wird cum Kapitalmassnahme gehandelt am 06.06.2025 und ex Kapitalmassnahme am 09.06.2025 The instrument 37P FR0010341032 FONCIERE INEA... ► Artikel lesen | |
03.06. | Spotlight Stock Market: Market Notice 101/25 - Information regarding the rights issue from CHOSA Oncology AB | 3 | Cision News | ||
02.06. | Chosa Oncology AB resolves on a directed issue of units and on a rights issue of units to provide funds for reaching several value-enhancing milestones | 3 | Cision News | ||
23.05. | CHOSA ONCOLOGY AB: CHOSA submits ESMO abstract on carboplatin response in breast cancer patients | 2 | Cision News | ||
13.05. | Notice of annual general meeting in Chosa Oncology AB | 2 | Cision News |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ADMA BIOLOGICS | 14,660 | +0,89 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
QIAGEN | 39,740 | +0,68 % | Kaum Impulse für die Qiagen NV-Aktie (37,58 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen... ► Artikel lesen | |
CG ONCOLOGY | 39,820 | -0,09 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,480 | -0,72 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
ARVINAS | 9,610 | +3,61 % | Arvinas Inc.: Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | ||
IMMUNOME | 12,380 | +7,93 % | Where Immunome Stands With Analysts | ||
JANUX THERAPEUTICS | 24,000 | +3,05 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
ARS PHARMACEUTICALS | 10,310 | +0,29 % | ARS Pharma secures $250M loan to accelerate Neffy rollout | ||
BIONTECH | 90,45 | +0,06 % | Achtung Übernahmen! BioTechs wie Evotec, PanGenomic Health, Pfizer und BioNTech im Fokus | Die BioTech-Branche ist in Aufruhr! Mit dem Wegfall von Blockbuster-Patenten drohen kräftige Umsatzrückgänge, die strategisch kompensiert werden müssen. Angetrieben durch wirtschaftlichen Druck und... ► Artikel lesen | |
TAYSHA GENE THERAPIES | 4,770 | -2,25 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome | Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized... ► Artikel lesen | |
EVOTEC | 6,744 | +2,00 % | Rheinmetall Aktie: Große Chance? - ABO Energy, Evotec, Funkwerk, MPC Capital und Redcare Pharmacy im Marktbericht Börse Frankfur | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 8,470 | +13,54 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
LENZ THERAPEUTICS | 48,740 | +0,87 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 65,18 | +10,89 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 47,010 | +6,41 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen |